Interplay between epigenetics & cancer metabolism

Vibhor Gupta, P. Gopinath, Mohd Askandar Iqbal, Sybille Mazurek, Kathryn E. Wellen, Rameshwar N.K. Bamezai

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Nutrient utilization is dramatically altered when cells receive signals to proliferate. Characteristic metabolic changes enable cells to meet the large biosynthetic demands associated with cell growth and division. Changes in rate-limiting glycolytic enzymes redirect metabolism to support growth and proliferation. Metabolic reprogramming in cancer is controlled largely by oncogenic activation of signal transduction pathways and transcription factors. Although less well understood, epigenetic mechanisms may seem to contribute to the regulation of metabolic gene expression in cancer. Reciprocally, accumulating evidence suggests that metabolic alterations may affect the epigenome. Understanding the relation between metabolism and epigenetics in cancer cells may open new avenues for anti-cancer strategies. In multi-cellular systems, molecular signals promoting cell growth and proliferation mediate the switch between catabolism and anabolism. Both normal proliferating and cancer cells must achieve high levels of macromolecular biosynthesis to provide the raw materials needed to produce new daughter cells. From a therapeutic view point, it is of great interest to determine metabolic differences that exist between normal proliferating cells and cancer cells. Cancer cells also exhibit significant alterations in the epigenome. Recent data indicate that cellular metabolism and epigenetic phenomenon are engaged in crosstalk [1, 2]. Considering current efforts to target both cancer metabolism and epigenetics, an understanding of the relationship between these two key features is of paramount importance [3, 4]. Here we discuss the role of cellular metabolism in regulation of the epigenome. Moreover, we discuss how epigenetic changes may contribute to establish cancer-specific metabolic features.

Original languageEnglish (US)
Pages (from-to)1706-1714
Number of pages9
JournalCurrent pharmaceutical design
Volume20
Issue number11
DOIs
StatePublished - Jan 1 2014

Fingerprint

Epigenomics
Neoplasms
Growth
Gene Expression Regulation
Cell Division
Signal Transduction
Transcription Factors
Cell Proliferation
Food
Enzymes

Keywords

  • Cancer metabolism
  • DNA methylation
  • Enzyme catalysis
  • Epigenetics
  • Glycolysis
  • Histone modification
  • Mitochondrial oxidative phosphorylation
  • TCA cycle
  • Therapeutic targeting

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Gupta, V., Gopinath, P., Iqbal, M. A., Mazurek, S., Wellen, K. E., & Bamezai, R. N. K. (2014). Interplay between epigenetics & cancer metabolism. Current pharmaceutical design, 20(11), 1706-1714. https://doi.org/10.2174/13816128113199990536

Interplay between epigenetics & cancer metabolism. / Gupta, Vibhor; Gopinath, P.; Iqbal, Mohd Askandar; Mazurek, Sybille; Wellen, Kathryn E.; Bamezai, Rameshwar N.K.

In: Current pharmaceutical design, Vol. 20, No. 11, 01.01.2014, p. 1706-1714.

Research output: Contribution to journalArticle

Gupta, V, Gopinath, P, Iqbal, MA, Mazurek, S, Wellen, KE & Bamezai, RNK 2014, 'Interplay between epigenetics & cancer metabolism', Current pharmaceutical design, vol. 20, no. 11, pp. 1706-1714. https://doi.org/10.2174/13816128113199990536
Gupta V, Gopinath P, Iqbal MA, Mazurek S, Wellen KE, Bamezai RNK. Interplay between epigenetics & cancer metabolism. Current pharmaceutical design. 2014 Jan 1;20(11):1706-1714. https://doi.org/10.2174/13816128113199990536
Gupta, Vibhor ; Gopinath, P. ; Iqbal, Mohd Askandar ; Mazurek, Sybille ; Wellen, Kathryn E. ; Bamezai, Rameshwar N.K. / Interplay between epigenetics & cancer metabolism. In: Current pharmaceutical design. 2014 ; Vol. 20, No. 11. pp. 1706-1714.
@article{7455b27c26d04f5b892e0a14535302fe,
title = "Interplay between epigenetics & cancer metabolism",
abstract = "Nutrient utilization is dramatically altered when cells receive signals to proliferate. Characteristic metabolic changes enable cells to meet the large biosynthetic demands associated with cell growth and division. Changes in rate-limiting glycolytic enzymes redirect metabolism to support growth and proliferation. Metabolic reprogramming in cancer is controlled largely by oncogenic activation of signal transduction pathways and transcription factors. Although less well understood, epigenetic mechanisms may seem to contribute to the regulation of metabolic gene expression in cancer. Reciprocally, accumulating evidence suggests that metabolic alterations may affect the epigenome. Understanding the relation between metabolism and epigenetics in cancer cells may open new avenues for anti-cancer strategies. In multi-cellular systems, molecular signals promoting cell growth and proliferation mediate the switch between catabolism and anabolism. Both normal proliferating and cancer cells must achieve high levels of macromolecular biosynthesis to provide the raw materials needed to produce new daughter cells. From a therapeutic view point, it is of great interest to determine metabolic differences that exist between normal proliferating cells and cancer cells. Cancer cells also exhibit significant alterations in the epigenome. Recent data indicate that cellular metabolism and epigenetic phenomenon are engaged in crosstalk [1, 2]. Considering current efforts to target both cancer metabolism and epigenetics, an understanding of the relationship between these two key features is of paramount importance [3, 4]. Here we discuss the role of cellular metabolism in regulation of the epigenome. Moreover, we discuss how epigenetic changes may contribute to establish cancer-specific metabolic features.",
keywords = "Cancer metabolism, DNA methylation, Enzyme catalysis, Epigenetics, Glycolysis, Histone modification, Mitochondrial oxidative phosphorylation, TCA cycle, Therapeutic targeting",
author = "Vibhor Gupta and P. Gopinath and Iqbal, {Mohd Askandar} and Sybille Mazurek and Wellen, {Kathryn E.} and Bamezai, {Rameshwar N.K.}",
year = "2014",
month = "1",
day = "1",
doi = "10.2174/13816128113199990536",
language = "English (US)",
volume = "20",
pages = "1706--1714",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "11",

}

TY - JOUR

T1 - Interplay between epigenetics & cancer metabolism

AU - Gupta, Vibhor

AU - Gopinath, P.

AU - Iqbal, Mohd Askandar

AU - Mazurek, Sybille

AU - Wellen, Kathryn E.

AU - Bamezai, Rameshwar N.K.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Nutrient utilization is dramatically altered when cells receive signals to proliferate. Characteristic metabolic changes enable cells to meet the large biosynthetic demands associated with cell growth and division. Changes in rate-limiting glycolytic enzymes redirect metabolism to support growth and proliferation. Metabolic reprogramming in cancer is controlled largely by oncogenic activation of signal transduction pathways and transcription factors. Although less well understood, epigenetic mechanisms may seem to contribute to the regulation of metabolic gene expression in cancer. Reciprocally, accumulating evidence suggests that metabolic alterations may affect the epigenome. Understanding the relation between metabolism and epigenetics in cancer cells may open new avenues for anti-cancer strategies. In multi-cellular systems, molecular signals promoting cell growth and proliferation mediate the switch between catabolism and anabolism. Both normal proliferating and cancer cells must achieve high levels of macromolecular biosynthesis to provide the raw materials needed to produce new daughter cells. From a therapeutic view point, it is of great interest to determine metabolic differences that exist between normal proliferating cells and cancer cells. Cancer cells also exhibit significant alterations in the epigenome. Recent data indicate that cellular metabolism and epigenetic phenomenon are engaged in crosstalk [1, 2]. Considering current efforts to target both cancer metabolism and epigenetics, an understanding of the relationship between these two key features is of paramount importance [3, 4]. Here we discuss the role of cellular metabolism in regulation of the epigenome. Moreover, we discuss how epigenetic changes may contribute to establish cancer-specific metabolic features.

AB - Nutrient utilization is dramatically altered when cells receive signals to proliferate. Characteristic metabolic changes enable cells to meet the large biosynthetic demands associated with cell growth and division. Changes in rate-limiting glycolytic enzymes redirect metabolism to support growth and proliferation. Metabolic reprogramming in cancer is controlled largely by oncogenic activation of signal transduction pathways and transcription factors. Although less well understood, epigenetic mechanisms may seem to contribute to the regulation of metabolic gene expression in cancer. Reciprocally, accumulating evidence suggests that metabolic alterations may affect the epigenome. Understanding the relation between metabolism and epigenetics in cancer cells may open new avenues for anti-cancer strategies. In multi-cellular systems, molecular signals promoting cell growth and proliferation mediate the switch between catabolism and anabolism. Both normal proliferating and cancer cells must achieve high levels of macromolecular biosynthesis to provide the raw materials needed to produce new daughter cells. From a therapeutic view point, it is of great interest to determine metabolic differences that exist between normal proliferating cells and cancer cells. Cancer cells also exhibit significant alterations in the epigenome. Recent data indicate that cellular metabolism and epigenetic phenomenon are engaged in crosstalk [1, 2]. Considering current efforts to target both cancer metabolism and epigenetics, an understanding of the relationship between these two key features is of paramount importance [3, 4]. Here we discuss the role of cellular metabolism in regulation of the epigenome. Moreover, we discuss how epigenetic changes may contribute to establish cancer-specific metabolic features.

KW - Cancer metabolism

KW - DNA methylation

KW - Enzyme catalysis

KW - Epigenetics

KW - Glycolysis

KW - Histone modification

KW - Mitochondrial oxidative phosphorylation

KW - TCA cycle

KW - Therapeutic targeting

UR - http://www.scopus.com/inward/record.url?scp=84903744836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903744836&partnerID=8YFLogxK

U2 - 10.2174/13816128113199990536

DO - 10.2174/13816128113199990536

M3 - Article

C2 - 23888952

AN - SCOPUS:84903744836

VL - 20

SP - 1706

EP - 1714

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 11

ER -